Anti-angiogenesis: The challenges ahead

MedGenMed Medscape General Medicine

Volumn 5, Issue 2, 2003, Pages

  Mariani, Sara M ^a  

^a Medscape Molecular Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (8 HYDROXY 6 METHOXY 1 OXO 1H 2 BENZOPYRAN 3 YL)PROPIONIC ACID; 2 METHOXYESTRADIOL; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CANERTINIB; CANSTATIN; CAPECITABINE; CETUXIMAB; COMBRETASTATIN; ENDOSTATIN; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY LM 609; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PACLITAXEL; RECOMBINANT ENDOSTATIN; SEMAXANIB; SU 668; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB;

ALOPECIA; ANGIOGENESIS; APOPTOSIS; BONE MARROW TOXICITY; BREAST CANCER; CANCER INHIBITION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; METASTASIS; MICROTUBULE; NONHUMAN; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RESISTANCE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 25144494093     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(Suppl 16):15-8.
2. Ferrara N. Role of vascular endothelial growth factor in psysiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29 (Suppl 16):10-4.
3. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-39.
4. Conti CJ. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer theraphy. The Oncologist 2002;7(Suppl 3):4-11.
5. Eder JP Jr, Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002;20:3772-84.
6. Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001;61:7669-74.
7. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003;21:223-31.
8. Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001;79-86.
9. Herbst RS, Hess KR, Tran HT et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002;20:3792-803.
10. Feldman AL, Alexander HR Jr, Yang JC, et al. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer. 2002;95:1637-43.
11. Ju JL, Coomber BL, Kerbel RS. A paradigm for therapy-induced microenviromental changes in solid tumors leading to drug resistance. Differentation. 2002;70:599-609.
12. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20:3804-14.
13. Davis DW, Shen Y, Mullani NA, et al. Quantitative analysis of biomarkers and changes in tumor blood flow define a biological dose for clinical trials of recombinant human endostatin. Program and abstracts of the Annual Meeting of the American Association for Cancer Research; April 5-9, 2003; Toronto, Ontario, Canada.
14. Mazzanti CM, Tandle A, Lorang D, et al. Study of the molecular mechanisms underlying angiogenesis inhibition by microarray analysis. Program and abstracts of the Annual Meeting of the American Association for Cancer Research; April 5-9, 2003; Toronto, Ontario, Canada.
15. Ratel D, Simard B, Dupre I, et al. Comparison of the transcriptomic signatures of three antiangiogenic agents neovastat, endostatin and angiostatin. Program and abstracts of the Annual Meeting of the American Association for Cancer Research; April 5-9, 2003; Toronto, Ontario, Canada.
16. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science. 2000;289:1197-202.
17. Shin SU, Cho HM, Kang YS, et al. Enhanced inhibition of tumor growth using targeted delivery of an antibody-endostatin fusion protein. Program and abstracts of the Annual Meeting of the American Association for Cancer Research; April 5-9, 2003; Toronto, Ontario, Canada.
18. Ziche M, Morbidelli L, Cantara S, Donnini S. Synthetic partial sequences of endostatin endowed with angiousupressive and angiostimulatory effects. Program and abstracts of the Annual Meeting of the American Association for Cancer Research; April 5-9, 2003; Toronto, Ontario, Canada.
19. Chen HX, Gore-Langton RE, Cheson BD. Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Huntingt). 2001;15:1017, 1023-6.
20. Authors not listed. Capecitabine/bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer: results of a phase III study. Clin Breast Cancer. 2003;3:375-7.
21. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin Oncol. 2003;21:60-5.
22. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2202;62:3408-16.
23. Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid. 2002;12:1063-70.
24. Itasaka S, Komaki R, Herbst, et al. Endostatin blocks endothelial repopulation after radiation therapy. Program and abstracts of the Annual Meeting of the American Association for Cancer Research; April 5-9, 2003; Toronto, Ontario, Canada.
25. Gustin DM, Winegarden J, Haraf D, et al. Phase I study of bevacizumab, fluorouracil, hydroxyurea and radiotherapy (B-FHX) for patients with poor prognosis head and neck cancer. Program and abstracts of the Annual Meeting of the American Association Research; April 5-9, 2003; Toronto, Ontario, Canada.
26. Ye C, Feng C, Liu X, et al. Enhancing antiangiogenic therapy with EGFR-inhibition strategies: dual attack on both endothelial cell and tumor cell compartments. Program and abstracts of the Annual Meeting of the American Association for Cancer Research; April 5-9, 2003; Toronto, Ontario, Canada.
27. Formento P, Fischel JL, Hannoun-Levi JM, et al. Antagonistic effects resulting from the dual targeting of EGFR and HER2 on hormone-refractory prostate cancer cells. Program and abstracts of the Annual Meeting of the American Association; April 5-9, 2003; Toronto, Ontario, Canada.
28. Cline E, Bicciato S, DiBello C, et al. Prediction of in vivo synergistic activity of anti-angiogenic compounds by gene expression profiling. Program and abstracts of the Annual meeting of the American Association for Cancer Research; April 5-9, 2003; Toronto, Ontario, Canada.
29. Yu JL, Coomber BL, Kerbel RS. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation. 2002;70:599-609.